
Celsion Corporation CLSN
Quarterly report 2025-Q3
added 11-13-2025
Celsion Corporation Total Current Liabilities 2011-2025 | CLSN
Annual Total Current Liabilities Celsion Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.79 M | 7.39 M | 10 M | 6.77 M | 6.75 M | 7.89 M | 6.11 M | 6.2 M | 8.42 M | 9.35 M | 10.1 M | 4.67 M | 5.01 M | 6.15 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 M | 4.67 M | 7.12 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.79 | 2.35 % | $ 795 M | ||
|
Aeglea BioTherapeutics
AGLE
|
54.1 M | - | - | $ 1.01 B | ||
|
Aclaris Therapeutics
ACRS
|
31.6 M | $ 3.04 | 4.83 % | $ 235 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Aptorum Group Limited
APM
|
4.34 M | $ 1.17 | 4.46 % | $ 6.38 M | ||
|
Aptevo Therapeutics
APVO
|
6.21 M | $ 0.93 | -8.81 % | $ 257 K | ||
|
Athersys
ATHX
|
29.9 M | - | 3.77 % | $ 22.4 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
BeiGene, Ltd.
BGNE
|
2.21 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | ||
|
Calithera Biosciences
CALA
|
14 M | - | -10.95 % | $ 876 K | ||
|
Cerevel Therapeutics Holdings
CERE
|
92.2 M | - | - | $ 7.29 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
BioVie
BIVI
|
2.27 M | $ 1.27 | -3.05 % | $ 1.88 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
72.8 M | - | -15.15 % | $ 60.3 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
174 M | $ 26.81 | 1.36 % | $ 1.3 B | ||
|
Anika Therapeutics
ANIK
|
31.1 M | $ 9.48 | 0.96 % | $ 139 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 0.18 | -25.03 % | $ 392 M | ||
|
Cortexyme
CRTX
|
9.57 M | - | -1.05 % | $ 67.1 M | ||
|
Catalyst Biosciences
CBIO
|
20 M | $ 12.37 | 2.06 % | $ 814 M | ||
|
CTI BioPharma Corp.
CTIC
|
81.1 M | - | - | $ 1.2 B | ||
|
Arena Pharmaceuticals
ARNA
|
66.3 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
1.68 B | $ 591.15 | 0.02 % | $ 44.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
63.1 M | $ 2.53 | -0.39 % | $ 15.9 M | ||
|
Celldex Therapeutics
CLDX
|
39.5 M | $ 26.83 | 0.94 % | $ 1.73 M | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M |